<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013181</url>
  </required_header>
  <id_info>
    <org_study_id>ATU Romiplostim registry</org_study_id>
    <nct_id>NCT01013181</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the &quot; Real-life &quot; : Result of the French Experience in 72 Adults</brief_title>
  <acronym>ATU-r</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paris 12 Val de Marne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henri Mondor University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to review the charts of the first 100 patients included in the
      french compassionate program including patients with Immune Thrombopenia receiving
      romiplostim.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        -  Subject has a diagnosis of ITP according to the American Society of Hematology
           guidelines (George et al., 1996).

        -  Subject is equal to or greater than 18 years of age.

        -  Before any study-specific procedure, the appropriate written informed consent must be
           obtained.

        -  Subject receiving romiplostim in the compassionate program

        -  Available follow-up of one-year

      Exclusion Criteria:

      â€¢Secondary ITP e.g: thrombopenia related to hepatitis C, HIV, Chronic Lymphocytic Leukemia...

      The goal of this study is to review retrospectively the charts of the 100 first patients
      including in this program in France during the period of January 2008 and July 2008.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP)</measure>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Thrombopenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary Immune Thrombopenia receiving romiplostim in a compasionnate program
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria:

               -  Subject has a diagnosis of ITP according to the American Society of Hematology
                  guidelines (George et al., 1996).

               -  Subject is equal to or greater than 18 years of age.

               -  Before any study-specific procedure, the appropriate written informed consent
                  must be obtained.

        Exclusion Criteria:

          -  Exclusion Criteria:

               -  Secondary ITP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Amgen Laboratory</name_title>
    <organization>Amgen Laboratory</organization>
  </responsible_party>
  <keyword>Immune Thrombopenia</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>romiplostim</keyword>
  <keyword>compassionate program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

